Financial Reports
Related Searches:
Filter by:
August 5, 2009
Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand.
Read More »
August 5, 2009
AMRI's total contract services revenue dropped 16% to $38.8 million in 2Q09
Read More »
July 29, 2009
Pharmaceutical sales were up 7% to $9.4 billion.
Read More »
July 28, 2009
Product sales in the quarter were down 2% to $3.6 billion.
Read More »
July 28, 2009
Pharmaceutical sales in the quarter in North America were $2.1 billion (+36%).
Read More »
July 23, 2009
Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%).
Read More »
July 23, 2009
Excluding the unfavorable impact of foreign exchange, earnings were up 2% for the quarter and first half.
Read More »
July 23, 2009
Myozyme revenue was $79.3 million, up from $67.4 million in 1Q09, reflecting the E.U. approval of production at the 4000 L scale.
Read More »
July 22, 2009
Pharmaceutical sales were $8.7 billion in the quarter (-11%). Seretide/Advair sales were flat at $1.9 billion.
Read More »
July 22, 2009
Pharmaceutical sales were down 9% to $10.1 billion. The negative impact of foreign exchange accounted for a drop of $1.1 billion, or approximately 9%.
Read More »
July 22, 2009
Product sales were up 2% to $5.1 billion, while alliance revenue rose 54% to $179.5 million, primarily due to Erbitux revenues through the ImClone acquisition.
Read More »
July 22, 2009
Product sales were up 29% to a record $1.6 billion, driven primarily by the antiviral franchise with product sales up 26% to $1.4 billion.
Read More »
July 22, 2009
New business awards in the quarter were $266 million, representing a book-to-bill ratio of 1.2.
Read More »
